SCHEMBL7151996

SCHEMBL7151996

OCCNC(=S)NCC1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
MMP1 P03956 1/20 0.43
MMP2 P08253 1/20 0.43
MMP3 P08254 1/20 0.43
MMP9 P14780 1/20 0.43
MMP8 P22894 1/20 0.43
CA9 Q16790 1/20 0.43
EPHX1 P07099 2/20 0.41
ALDH1A1 P00352 3/20 0.40
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
HTT P42858 2/20 0.40
HPGD P15428 1/20 0.40
ALOX12 P18054 1/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
CYP2D6 P10635 1/20 0.38
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6539544 0.98 CA12 (0.46) CA12CA1CA2MMP1MMP2
SCHEMBL6538230 0.98 CA12 (0.46) CA12CA1CA2MMP1MMP2
SCHEMBL7783075 0.85 CA12 (0.55) CA12CA1CA2MMP1MMP2
SCHEMBL15224176 0.78 CYP2D6 (0.45) CA12CA1CA2MMP1MMP2
SCHEMBL15224173 0.75 CA2 (0.47) CA12CA1CA2MMP1MMP2
SCHEMBL6541454 0.75 KDM4E (0.35) MAPTSMN1; SMN2L3MBTL1RAB9A
SCHEMBL8393028 0.75 SMN1; SMN2 (0.45) CA12CA1CA2MMP1MMP2
SCHEMBL942983 0.75 L3MBTL1 (0.43) CA12CA1CA2CA9ALDH1A1
SCHEMBL13003047 0.73 LMNA (0.50) CA12CA1CA2MMP1MMP2
SCHEMBL8394060 0.73 SMN1; SMN2 (0.48) CA12CA1CA2MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6534542-B2 For alleviating chronic pain and allodynia and have no or only minimal cardivascular and/or sedatory activity ALLERGEN SALES, INC. 2003-03-18 US disclosed
US-20020161051-A1 (2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors ALLERGAN SALES, INC. 2002-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161051-A1 (2-hydroxy)ethyl-thioureas useful as modulators of alpha2B adrenergic receptors ADRA2B, ADRB2, ADRA2C CA12 4721/4885CA1 4607/4885CA2 2985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.